Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARIA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)

Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ARIA Guru Trades in Q2 2016

Steven Cohen 300,000 sh (New)
Chuck Royce 375,352 sh (unchged)
Michael Price 1,075,000 sh (unchged)
Paul Tudor Jones 21,400 sh (-20.94%)
Jim Simons 81,696 sh (-83.57%)
» More
Q3 2016

ARIA Guru Trades in Q3 2016

Joel Greenblatt 154,887 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 1,358,181 sh (+1562.48%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Michael Price 940,000 sh (-12.56%)
Chuck Royce 269,352 sh (-28.24%)
» More
Q4 2016

ARIA Guru Trades in Q4 2016

Joel Greenblatt 210,936 sh (+36.19%)
Michael Price 940,000 sh (unchged)
Jim Simons 762,481 sh (-43.86%)
Chuck Royce 55,502 sh (-79.39%)
» More
Q1 2017

ARIA Guru Trades in Q1 2017

Louis Moore Bacon Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Michael Price Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2017-03-31 Sold Out 1.42%$12.37 - $23.99 $ 23.997%0
Joel Greenblatt 2017-03-31 Sold Out 0.03%$12.37 - $23.99 $ 23.997%0
Joel Greenblatt 2016-12-31 Add 36.19%0.01%$8.67 - $14.19 $ 23.9999%210,936
Michael Price 2016-09-30 Reduce -12.56%0.13%$7.03 - $14.14 $ 23.99139%940,000
Joel Greenblatt 2016-09-30 New Buy0.03%$7.03 - $14.14 $ 23.99139%154,887
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Traded in other countries:APS.Germany, ARIA.Switzerland, 0R2K.UK,
Headquarter Location:USA
ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788.

ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $186.24
EPS (TTM) $ -0.18
Short Percentage of Float16.07%
52-Week Range $4.67 - 23.99
Shares Outstanding (Mil)194.20

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 197 205 282 394
EPS ($) -0.44 -0.19 -0.29 0.07
EPS without NRI ($) -0.44 -0.19 -0.29 0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for ARIA


Articles On GuruFocus.com
The Gabelli ABC Fund Merger and Arbitrage 1st Quarter Commentary May 10 2017 
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17 Aug 22 2017
What Sprycel Could Mean for Bristol-Myers Squibb Jul 10 2017
​SEC charges two former Ariad executives with insider trading Jun 27 2017
Analyzing Incyte’s Revenue Streams in 1Q17 Jun 15 2017
Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale Apr 06 2017
Amgen's Blincyto sBLA Secures FDA Priority Review Mar 30 2017
Who Is Incyte Collaborating With? Mar 01 2017
Two Great Stock Ideas in the IBB Biotech ETF Feb 15 2017
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib Feb 07 2017
Why Ariad Pharmaceuticals Stock Nearly Doubled in January Feb 06 2017
Ariad Submits Marketing Application to EU Agency Feb 06 2017
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European... Feb 06 2017
Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy... Feb 01 2017
Ariad mum on layoffs in letter to employees: ‘It’s business as usual’ Jan 25 2017
Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC Jan 20 2017
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017
Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)? Jan 20 2017
5 Expensive Drugs That Could End Up in Trump's Crosshairs Jan 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat